CASE STUDY PRA Delivers Study Start-up Success Contingency Plan Leads to Timely FPIPRA Delivers Study Start-up Success Contingency Plan Leads to Timely FPI Primary Endpoint To evaluate the clinical efficacy of the Study Drug with MTX in subjects with active RA who have had an inadequate response to DMARD therapy PRA Services Full Service Indication Rheumatoid Arthritis Drug Class Small Molecule Study Phase IIa Business Segment Product Registration Regions North America Central Europe Eastern Europe Asia Pacific (Incl. India) STUDY DESCRIPTION A Phase IIa randomized double-blind, placebo controlled, multi-center study to evaluate the efficacy, safety, and tolerability of Study Drug when given Methotrexate (MTX) to subjects with active rheumatoid arthritis (RA) who have had

Join for free to read